Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Our aim is to develop new and improved therapies that offer benefits over existing treatment options
Roche has a portfolio of therapies for the treatment of cancer as well as diseases including haemophilia, central nervous system disorders, lung disorders and inflammatory diseases.
Our products currently supported on rocheresources.co.uk
Prescribing Information:
RoACTEMRA (tocilizumab) RA/GCA
RoACTEMRA (tocilizumab) pJIA/sJIA
RoACTEMRA (tocilizumab) CRS
Prescribing Information
TECENTRIQ®▼(atezolizumab) Great Britain
TECENTRIQ®▼ (atezolizumab) Northern Ireland
Further Information
Congress and Meetings
Highlights from the latest international and national congresses and Roche-organised meetings.
M-GB-00004871
Date of preparation: September 2021